Free Trial

Chi Fong Analyst Performance

Analyst at Bank of America

Chi Fong is a stock analyst at Bank of America in the healthcare sector, covering 2 publicly traded companies. Over the past year, Chi Fong has issued 1 stock ratings, including and buy recommendations. While full access to Chi Fong's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Chi Fong's coverage history, rating activity, and performance tendencies - helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
2 Last 1 Years
Buy Recommendations
50.00% 1 Buy Ratings
Companies Covered
2 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy50.0%1 ratings
Hold50.0%1 ratings
Sell0.0%0 ratings

Out of 2 total stock ratings issued by Chi Fong at Bank of America, the majority (50.0%) have been Buy recommendations, followed by 50.0% Hold.

Best & Worst Calls

This analyst does not have any ratings with enough history to determine best and worst calls.

Exchange Coverage

ExchangePercentageCount
NASDAQ
100.0% of companies on NASDAQ
2 companies

Chi Fong, an analyst at Bank of America, currently covers 2 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Healthcare
2 companies
100.0%

Chi Fong of Bank of America specializes in stock coverage within the Healthcare sector.

Coverage Industries

IndustryPercentage
PHARMACEUTICALS
1 company
50.0%
BIOTECHNOLOGY
1 company
50.0%

Chi Fong's Ratings History at Bank of America

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
0 Results
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Supernus Pharmaceuticals, Inc. stock logo
SUPN
Supernus Pharmaceuticals
11/9/2026Initiated Coverage$26.16$47.00Buy
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
9/18/2025Boost Price Target$15.28$16.50Neutral